Sutro Biopharma Inc is a pioneering clinical-stage company focused on the development of innovative cancer treatments. It specializes in creating antibody drug conjugates (ADCs) with its unique cell-free protein synthesis platforms, XpressCF and XpressCF+. The company is advancing a portfolio of product candidates targeting various cancers, including multiple myeloma, non-Hodgkin lymphoma, ovarian, and endometrial cancers. Sutro Biopharma is also engaged in strategic collaborations with industry leaders to enhance its research in immuno-oncology and solid tumors, demonstrating its commitment to advancing cancer care.